Mean differences in clinical and lung function parameters in the fluticasone/salmeterol (FP/S) group compared with the fluticasone (FP) group over the 1 year treatment period
| Mean difference FP/S − FP | p value | |
|---|---|---|
| Values are expressed as *mean or †geometric mean (SE). | ||
| PEF, peak expiratory flow; FEV1, forced expiratory volume in 1 second; PC20histamine, concentration of histamine provoking a fall in FEV1 of at least 20%. | ||
| PEF morning (l/min)* | 29 (9) | <0.001 |
| PEF evening (l/min)* | 36 (9) | <0.001 |
| Symptom score morning (scale 0–4)* | −0.1 (0.1) | 0.02 |
| Symptom score evening (scale 0–5)* | −0.2 (0.1) | 0.01 |
| Short acting β2 agonist usage(puffs/day)* | −0.9 (0.3) | <0.001 |
| FEV1 (% predicted)* | 2.7 (1.5) | 0.07 |
| PC20histamine (doubling doses)† | 0.7 (0.3) | 0.02 |